Found: 36
Select item for more details and to access through your institution.
Locally Advanced, Unresectable Non-Small Cell Lung Cancer.
- Published in:
- Current Oncology Reports, 2020, v. 22, n. 4, p. 1, doi. 10.1007/s11912-020-0882-3
- By:
- Publication type:
- Article
Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 9, p. 7781, doi. 10.3390/ijms24097781
- By:
- Publication type:
- Article
Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features.
- Published in:
- Frontiers in Oncology, 2024, p. 01, doi. 10.3389/fonc.2024.1324057
- By:
- Publication type:
- Article
Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231161409
- By:
- Publication type:
- Article
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).
- Published in:
- Clinical Lung Cancer, 2021, v. 22, n. 6, p. 601, doi. 10.1016/j.cllc.2021.06.006
- By:
- Publication type:
- Article
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).
- Published in:
- 2019
- By:
- Publication type:
- journal article
Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 87, doi. 10.2147/LCTT.S463429
- By:
- Publication type:
- Article
Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/1758835921992976
- By:
- Publication type:
- Article
Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/1758835921992976
- By:
- Publication type:
- Article
Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 7, p. 1965, doi. 10.1007/s00262-020-02820-4
- By:
- Publication type:
- Article
Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 6, p. e2215589, doi. 10.1001/jamanetworkopen.2022.15589
- By:
- Publication type:
- Article
Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 6, p. 1, doi. 10.1001/jamanetworkopen.2022.15589
- By:
- Publication type:
- Article
Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy.
- Published in:
- Cancers, 2024, v. 16, n. 5, p. 935, doi. 10.3390/cancers16050935
- By:
- Publication type:
- Article
New Actions on Actionable Mutations in Lung Cancers.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities.
- Published in:
- Cancers, 2023, v. 15, n. 3, p. 612, doi. 10.3390/cancers15030612
- By:
- Publication type:
- Article
TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR -Mutant Non-Small Cell Lung Cancer.
- Published in:
- Cancers, 2022, v. 14, n. 24, p. 6127, doi. 10.3390/cancers14246127
- By:
- Publication type:
- Article
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced EGFR -Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis
- Published in:
- Cancers, 2022, v. 14, n. 19, p. 4894, doi. 10.3390/cancers14194894
- By:
- Publication type:
- Article
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients.
- Published in:
- NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00720-9
- By:
- Publication type:
- Article
Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 5, p. 1, doi. 10.1002/cam4.7069
- By:
- Publication type:
- Article
Sequential Lymphomas or Clonally Unrelated Richter Syndrome of Chronic Lymphocytic Leukemia Into Mantle Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 5, p. 606, doi. 10.1016/j.clml.2013.04.007
- By:
- Publication type:
- Article
Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes.
- Published in:
- Cancer Innovation, 2024, v. 3, n. 3, p. 1, doi. 10.1002/cai2.112
- By:
- Publication type:
- Article
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 10, p. 1679, doi. 10.1038/s41416-024-02615-9
- By:
- Publication type:
- Article
Aspergillus pseudomembranous necrotizing tracheitis.
- Published in:
- American Journal of Hematology, 2013, v. 88, n. 3, p. 242, doi. 10.1002/ajh.23332
- By:
- Publication type:
- Article
Antibody-drug conjugates in lung cancer: dawn of a new era?
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-022-00338-9
- By:
- Publication type:
- Article
ctDNA Dynamics, Prognostic Markers, and Mechanisms of Resistance in Tepotinib-treated MET exon 14 (METex14) Skipping NSCLC in the VISION Trial.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2023, v. 14, n. 11, p. 352
- By:
- Publication type:
- Article
Intracranial Activity of Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non-- Small-Cell Lung Cancer (NSCLC) Enrolled in VISION.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2022, v. 13, n. 11, p. 376
- By:
- Publication type:
- Article
Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck.
- Published in:
- Head & Neck, 2021, v. 43, n. 5, p. 1592, doi. 10.1002/hed.26626
- By:
- Publication type:
- Article
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers.
- Published in:
- Journal of NeuroImmune Pharmacology, 2020, v. 15, n. 1, p. 27, doi. 10.1007/s11481-019-09891-w
- By:
- Publication type:
- Article
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers.
- Published in:
- Oncologist, 2024, v. 29, n. 6, p. e779, doi. 10.1093/oncolo/oyac080
- By:
- Publication type:
- Article
New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non‐Small Cell Lung Cancer.
- Published in:
- Oncologist, 2020, v. 25, n. 10, p. 822, doi. 10.1634/theoncologist.2020-0760
- By:
- Publication type:
- Article
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components.
- Published in:
- Science Translational Medicine, 2020, v. 12, n. 559, p. 1, doi. 10.1126/scitranslmed.aaz4589
- By:
- Publication type:
- Article